Arkema SA (OTCMKTS:ARKAY - Get Free Report) gapped up before the market opened on Friday . The stock had previously closed at $69.77, but opened at $72.50. Arkema shares last traded at $72.50, with a volume of 305 shares traded.
Analysts Set New Price Targets
A number of research firms recently issued reports on ARKAY. Kepler Capital Markets downgraded shares of Arkema from a "strong-buy" rating to a "hold" rating in a report on Friday, February 27th. Zacks Research downgraded shares of Arkema from a "hold" rating to a "strong sell" rating in a report on Tuesday, January 6th. Finally, The Goldman Sachs Group upgraded shares of Arkema from a "hold" rating to a "buy" rating in a report on Tuesday, February 10th. Two research analysts have rated the stock with a Buy rating, three have issued a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Reduce".
Check Out Our Latest Analysis on ARKAY
Arkema Price Performance
The stock has a market cap of $5.51 billion, a PE ratio of 83.31, a P/E/G ratio of 1.71 and a beta of 0.84. The company has a debt-to-equity ratio of 0.54, a current ratio of 2.13 and a quick ratio of 1.63. The firm's 50 day moving average price is $67.37 and its two-hundred day moving average price is $62.90.
About Arkema
(
Get Free Report)
Arkema SA is a global specialty chemicals and advanced materials company headquartered in Colombes, France. Established in 2004 as a spin-off from Total's chemicals division, the company offers a broad portfolio of high-performance materials designed to improve durability, thermal and chemical resistance, and environmental performance across diverse industries.
Arkema's operations are organized into four core segments. Adhesive Solutions delivers bonding, sealing, and coating technologies for markets such as packaging, medical devices, and consumer goods.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Arkema, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arkema wasn't on the list.
While Arkema currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.